Pharmacodynamic-Pharmacokinetic Integration as a Guide to Medicinal Chemistry

被引:24
|
作者
Gabrielsson, Johan [1 ,5 ]
Fjellstrom, Ola [2 ]
Ulander, Johan [2 ]
Rowley, Michael [3 ]
Van der Graaf, Piet H. [4 ]
机构
[1] AstraZeneca R&D, Discovery DMPK, S-43183 Molndal, Sweden
[2] AstraZeneca R&D, Lead Generat, S-43183 Molndal, Sweden
[3] AstraZeneca R&D, Med Chem, S-43183 Molndal, Sweden
[4] Pfizer Ltd, Sandwich Res Unit, Dept Pharmacokinet Dynam & Metab PDM & Global Pha, Sandwich CT13 9NJ, Kent, England
[5] AstraZeneca R&D, BAC, S-43183 Molndal, Sweden
关键词
Mechanism-based PKPD modelling; potency; efficacy; lipophilicity; structure-activity relationship; turnover models; effect compartment models; occupancy binding models; PLASMA-PROTEIN BINDING; PHARMACOLOGY; RATS; MODEL; TIME;
D O I
10.2174/156802611794480864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A primary objective of pharmacokinetic-pharmacodynamic (PKPD) reasoning is to identify key in vivo drug and system properties, enabling prediction of the magnitude and time course of drug responses under physiological and pathological conditions in animals and man. Since the pharmacological response generated by a drug is highly dependent on the actual system used to study its action, knowledge about its potency and efficacy at a given concentration or dose is insufficient to obtain a proper understanding of its pharmacodynamic profile. Hence, the output of PKPD activities extends beyond the provision of quantitative measures (models) of results, to the design of future protocols. Furthermore, because PKPD integrates DMPK (e. g. clearance) and pharmacology (e. g. potency), it provides an anchor point for compound selection, and, as such, should be viewed as an important weapon in medicinal chemistry. Here we outline key PK concepts relevant to PD, and then consider real-life experiments to illustrate the importance to the medicinal chemist of data obtained by PKPD. Useful assumptions and potential pitfalls are described, providing a holistic view of the plethora of determinants behind in vitro-in vivo correlations. By condensing complexity to simplicity, there are not only consequences for experimental design, and for the ranking and design of compounds, but it is also possible to make important predictions such as the impact of changes in drug potency and kinetics. In short, by using quantitative methods to tease apart pharmacodynamic complexities such as temporal differences and changes in plasma protein binding, it is possible to target the changes necessary for improving a compound's profile.
引用
收藏
页码:404 / 418
页数:15
相关论文
共 50 条
  • [31] Pharmacokinetic-Pharmacodynamic Modeling of Propofol in Children
    Rigouzzo, Agnes
    Servin, Frederique
    Constant, Isabelle
    ANESTHESIOLOGY, 2010, 113 (02) : 343 - 352
  • [32] Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis
    Fujii, Motoki
    Karumai, Toshiyuki
    Yamamoto, Ryohei
    Kobayashi, Eri
    Ogawa, Kenta
    Tounai, Mayuko
    Lipman, Jeffrey
    Hayashi, Yoshiro
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 415 - 430
  • [33] Pharmacokinetic and Pharmacodynamic Comparison of Intravenous and Inhaled Caspofungin
    Yu, Iching G.
    O'Brien, Sean E.
    Ryckman, David M.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2021, 34 (03) : 197 - 203
  • [34] Population pharmacokinetic-pharmacodynamic analysis of givinostat
    Fiorentini, Francesco
    Germani, Massimiliano
    Del Bene, Francesca
    Pellizzoni, Cinzia
    Cazzaniga, Sara
    Rocchetti, Maurizio
    Bettica, Paolo
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 229 - 238
  • [35] Population pharmacokinetic and pharmacodynamic analysis in allergic diseases
    Lovern, Mark
    Sargentini-Maier, Maria-Laura
    Otoul, Christian
    Watelet, Jean-Baptiste
    DRUG METABOLISM REVIEWS, 2009, 41 (03) : 475 - 485
  • [36] Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview
    Jeon, Jae Yoon
    Ayyar, Vivaswath S.
    Mitra, Amitava
    PHARMACEUTICAL RESEARCH, 2022, 39 (08) : 1749 - 1759
  • [37] Pharmacokinetic and pharmacodynamic study of intranasal and intravenous dexmedetomidine
    Li, A.
    Yuen, V. M.
    Goulay-Dufay, S.
    Sheng, Y.
    Standing, J. F.
    Kwok, P. C. L.
    Leung, M. K. M.
    Leung, A. S.
    Wong, I. C. K.
    Irwin, M. G.
    BRITISH JOURNAL OF ANAESTHESIA, 2018, 120 (05) : 960 - 968
  • [38] Fluorine in medicinal chemistry
    Böhm, HJ
    Banner, D
    Bendels, S
    Kansy, M
    Kuhn, B
    Müller, K
    Obst-Sander, U
    Stahl, M
    CHEMBIOCHEM, 2004, 5 (05) : 637 - 643
  • [39] Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation
    Kipourou, Maria
    Begou, Olga
    Manika, Katerina
    Ismailos, Georgios
    Kontou, Paschalina
    Pitsiou, Georgia
    Gika, Helen
    Kioumis, Ioannis
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [40] Does curcumin or pindolol potentiate fluoxetines antidepressant effect by a pharmacokinetic or pharmacodynamic interaction
    Murad, H. A. S.
    Suliaman, M. I.
    Abdallah, H.
    Abdulsattar, May
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 76 (03) : 203 - 210